EUVIMEDEUVIMED entdecken
Vergleichsstudie

Clinical Outcomes in Type 2 Diabetes Patients After Acute Myocardial Infarction: A Comparison of Sodium–Glucose Cotransporter 2 Inhibitors vs. Non‐Users

Hsin-Fu Lee iD, Yi-Hsin Chan, Tzyy-Jer Hsu, Chi Chuang, Pei-Ru Li, Yung-Hsin Yeh, Hung-Chi Su, Fu-Chih Hsiao, Lai-Chu See iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3304 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Hsin-Fu Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, New Taipei City Municipal Tucheng Hospital, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Myocardial Infarction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan, Chang Gung Memorial Hospital, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To compare clinical outcomes in patients with type 2 diabetes (T2D) after acute myocardial infarction (AMI) using sodium–glucose cotransporter‐2 inhibitors (SGLT2i) vs. non‐use of SGLT2i. A national cohort study based on the Taiwan National Health Insurance Research Database enrolled 944 patients with T2D who had experienced AMI and were treated with SGLT2i and 8,941 patients who did not receive SGLT2i, respectively, from May 1, 2016, to December 31, 2019. We used propensity score matching to balance covariates across study groups. The follow‐up period was from the index date to the independent occurrence of the study outcomes, discontinuation of the index drug, or the end of the study period (December 31, 2020), whichever occurred first. The SGLT2i group exhibited a significantly lower incidence of cardiovascular death (0.865% per year vs. 2.048% per year; hazard ratio (HR): 0.42; 95% confidence interval (CI): 0.24–0.76; P = 0.0042), heart failure hospitalization (1.987% per year vs. 3.395% per year; HR: 0.59; 95% CI: 0.39–0.89; P = 0.0126), and all‐cause mortality (3.406% per year vs. 4.981% per year, HR: 0.69; 95% CI: 0.50–0.95; P = 0.0225) compared with the non‐SGLT2i group. There were no significant differences between the two groups in the incidence of AMI, ischemic stroke, coronary revascularization, major adverse cardiovascular events, composite renal outcomes, or lower limb amputation. These findings suggest that the use of SGLT2i may have favorable effects on clinical outcomes in patients with T2D after AMI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsMyocardial InfarctionHumansMaleFemaleMiddle AgedAgedTaiwanTreatment OutcomeCohort StudiesRetrospective StudiesHospitalizationIncidenceDatabases, Factual

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, New Taipei City Municipal Tucheng Hospital, New Taipei City, Taiwan.
  • The Cardiovascular Department, Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
  • Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
  • Microscopy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan.
  • Department of Public Health, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.

ORCID-Profile: Hsin-Fu Lee, Lai-Chu See

Förderung

  • Ministry of Science and Technology, Taiwan
  • Chang Gung Memorial Hospital
  • National Science and Technology Council

Zitieren

APA

Lee, H. F., Chan, Y. H., Hsu, T. J., Chuang, C., Li, P. R., Yeh, Y. H., Su, H. C., Hsiao, F. C., & See, L. C. (2024). Clinical Outcomes in Type 2 Diabetes Patients After Acute Myocardial Infarction: A Comparison of Sodium–Glucose Cotransporter 2 Inhibitors vs. Non‐Users. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3304

Vancouver

Lee HF, Chan YH, Hsu TJ, Chuang C, Li PR, Yeh YH, et al. Clinical Outcomes in Type 2 Diabetes Patients After Acute Myocardial Infarction: A Comparison of Sodium–Glucose Cotransporter 2 Inhibitors vs. Non‐Users. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3304

BibTeX
@article{Lee2024,
  author = {Lee, Hsin-Fu and Chan, Yi-Hsin and Hsu, Tzyy-Jer and Chuang, Chi and Li, Pei-Ru and Yeh, Yung-Hsin and Su, Hung-Chi and Hsiao, Fu-Chih and See, Lai-Chu},
  title = {Clinical Outcomes in Type 2 Diabetes Patients After Acute Myocardial Infarction: A Comparison of Sodium–Glucose Cotransporter 2 Inhibitors vs. Non‐Users},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3304}
}
Kostenlos starten →